 | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
| Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
Insider Trading - Keros Therapeutics Inc. (KROS)
| | "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-04-13 Purchase | 2020-04-13 5:12 pm | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 375,200 | $16 | $6,003,200 | 1,119,812 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:13 pm | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:15 pm | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 120,000 | $16 | $1,920,000 | 2,013,102 (Indirect Direct) | View |
| 2020-04-13 Purchase | 2020-04-13 5:16 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:17 pm | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 375,200 | $16 | $6,003,200 | 1,119,812 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:18 pm | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:19 pm | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 20,000 | $16 | $320,000 | 243,856 (Direct) | View |
| 2020-04-13 Purchase | 2020-04-13 5:29 pm | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 120,000 | $16 | $1,920,000 | 2,013,102 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2020-04-07 Option Award | 2020-04-08 9:00 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 241,222 | $16 | 241,222 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:01 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 18,430 | $16 | 18,430 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:02 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith CFO | 18,430 | $16 | 133,622 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:02 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith CFO | 133,622 | $16 | 133,622 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:03 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 696,569 | $16 | 696,569 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 744,612 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 148,922 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 744,612 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 148,922 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 276,459 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 184,305 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 205,962 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 137,308 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 67,015 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 44,676 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 276,459 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 184,305 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 205,962 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 137,308 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 67,015 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 44,676 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 1,382,295 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 343,270 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 167,537 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 1,382,295 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 343,270 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 167,537 | $0 | 2,013,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 744,612 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 148,922 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 744,612 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 148,922 | $0 | 1,119,812 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 1,363,542 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 663,825 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 737,226 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 169,307 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 82,425 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 91,538 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 68,654 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 163,612 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 88,460 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 79,653 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 36,858 | $0 | 149,262 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:19 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 11,169 | $0 | 243,856 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:19 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 11,169 | $0 | 243,856 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 1,382,295 | $0 | 2,013,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 343,270 | $0 | 2,013,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 167,537 | $0 | 2,013,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 1,382,295 | $0 | 2,013,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 343,270 | $0 | 2,013,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 167,537 | $0 | 2,013,102 (Direct) | View |
| 2020-05-29 Option Award | 2020-05-29 5:19 pm | N/A 2030-05-29 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 8,500 | $28.74 | 8,500 (Direct) | View |